Antibodies useful in passive influenza immunization

ABSTRACT

Specific monoclonal antibodies and fragments including bispecific antibodies thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.

RELATED APPLICATION

This application claims benefit of U.S. application Ser. No. 61/567,046filed 5 Dec. 2011 which is incorporated herein by reference in itsentirety.

TECHNICAL FIELD

The invention relates to the field of passive immunization againstinfluenza. More particularly, specific antibodies that bind near to theHA₀ maturation cleavage site consensus sequence of influenzahemagglutinin A, including antibodies secreted by human cells aredescribed.

BACKGROUND ART

The hemagglutinin protein (HA) of influenza virus has a globular headdomain which is highly heterogeneous among flu strains and a stalkregion containing a fusion site which is needed for entry into thecells. HA is present as a trimer on the viral envelope. The uncleavedform of hemagglutinin protein (HA₀) is activated by cleavage by trypsininto HA₁ and HA₂ portions to permit the fusion site to effect virulence.The two cleaved portions remain coupled using disulfide bonds butundergo a conformational change in the low pH environment of the hostcell endosomal compartment which leads to fusion of the viral and hostcell membranes.

The cleavage site contains a consensus sequence that is shared both byinfluenza A and influenza B and by the various strains of influenza Aand B. The uncleaved hemagglutinin protein trimer (HA₀) is referred toas the inactivated form, whereas when cleaved into HA₁ and HA₂ portions,the hemagglutinin protein is referred to as being in the activated form.

Bianchi, E., et al., J. Virol. (2005) 79:7380-7388 describe a“universal” influenza B vaccine based on the consensus sequence of thiscleavage site wherein a peptide comprising this site was able to raiseantibodies in mice when conjugated to the outer membrane protein complexof Neisseria meningitidis. Monoclonal antibodies which appear to bind tothe consensus sequence were also described. In addition, successfulpassive transfer of antiserum was observed in mice. Other prior artvaccines, such as those described in WO2004/080403 comprising peptidesderived from the M2 and/or HA proteins of influenza induce antibodiesthat are either of weak efficacy or are not effective across strains.

Antibodies described in the art which bind the HA stalk region involvethose developed by Crucell, CR6261 and CR8020 described in Throsby, M.,et al., PLoS One (2008) 3:e3942, Ekiert, D. C., et al., Science (2011)333:843-850, and Sui, J., et al., Nat. Struct. Mol. Biol. (2009)16:265-273. An MAB has also been developed against the conserved M2Eantigen as described by Grandea, A. G., et al., PNAS USA (2010)107:12658-12663. M2E is on the surface of infected cells and is also thetarget of amantadine and rimantadine. Drug resistance has occurredagainst these antibiotics which suggests that this target does not servean essential function.

An additional antibody has been described by the Lanzavecchia Group:Corti, D., et al., Science (2011) 333:850-856 which binds andneutralizes both Group 1 and Group 2 strains of influenza A, but thepotency is not as high as those described herein as shown in theexamples below. In addition, an MAB that is immunoreactive against bothinfluenza A and B as described in Dreyfus, C., et al., Science (2012)337:1343-1348 has less potency than those described below.

PCT application publication No. WO2011/160083, incorporated herein byreference, describes monoclonal antibodies that are derived from humancells and useful in passive vaccines. The antibodies show highaffinities of binding to influenza viral clade H1, which is in Group 1,and some of the antibodies also show high affinities to H9, also inGroup 1 and/or to H7 in Group 2 and/or H2 in Group 1. Some of theantibodies disclosed bind only the inactivated trimer form, presumablyat the consensus cleavage region, while others are able to bindactivated hemagglutinin protein which has already been cleaved.

There remains a need for antibodies that bind additional clades and showenhanced affinity thereto.

DISCLOSURE OF THE INVENTION

The invention provides monoclonal antibodies that bind trimersrepresentative of either or both Group 1 and Group 2 of influenza A withenhanced affinity. Such antibodies are able to confer passive immunityin the event of a pandemic caused, for example, by a previouslyunidentified influenza strain or a strain against which protection isnot conferred by the seasonal vaccines currently available. As at leastsome of the antibodies bind across many strains, indicative of targetingan essential site, they are likely to bind even previously unencounteredstrains. Such antibodies are also useful to ameliorate or preventinfection in subjects for whom vaccination failed to produce a fullyprotective response or who are at high risk due to a weak immune system(e.g., the very young, the elderly, transplant patients, cancer or HIVchemotherapy treated patients).

Thus, in one aspect, the invention is directed to binding moieties,notably monoclonal antibodies or immunoreactive fragments thereof thatare broadly crossreactive with influenza A virus of Group 1 includingH1, H2, H5, H6, H8, H9, H11, H13, H16 or Group 2 including H3 and H7 astype specimens, or that show cross-Group reactivity. Some of theantibodies illustrated below bind to an epitope contained in the HA₀protein specifically and recognize the native trimeric form of HA, aswell as the activated form.

Particularly important are bispecific antibodies and fragments thereofwhich are able to enhance the range of viral clades that can be boundspecifically.

As is well understood in the art, non-immunoglobulin based proteins mayhave similar epitope recognition properties as antibodies and can alsoprovide suitable embodiments, including binding agents based onfibronectin, transferrin or lipocalin. Nucleic acid based moieties, suchas aptamers also have these binding properties.

In other aspects, the invention is directed to methods to use thebinding moieties of the invention for passively inhibiting viralinfection in subjects that are already exposed to the virus or that arealready infected. The invention is also directed to recombinantmaterials and methods to produce antibodies or fragments.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the art-known classification of influenza virus into groupsof significant clades.

FIG. 2 shows the results of binding by MAB579 in vitro to various H7 andH3 strains, both representing Group 2.

FIGS. 3A and 3B show two lead mAbs, MAB53 (Group 1) and MAB579 (Group 2)have sub-nM affinity across clades spanning the respective Groups.

FIGS. 4A and 4B contrast the neutralizing activity of MAB486 and MAB579.As shown in FIG. 4A, MAB486, as well as a polyclonal preparation fromrabbit immunization are effective in neutralizing H1N1 only in theabsence of trypsin. In contrast, FIG. 4B shows that MAB579 is effectiveboth in the presence and absence of trypsin.

FIG. 5 is a diagram of the bispecific antibody that comprises thevariable regions of MAB579 and MAB53.

FIGS. 6A-6E show the in vivo efficacy of MAB53, MAB579, mixtures ofthese, and the bispecific antibody shown in FIG. 5.

MODES OF CARRYING OUT THE INVENTION

The present invention provides useful binding moieties, includingantibodies and fragments thereof as well as effective means to identifycells that secrete such antibodies so that the relevant coding sequencescan be retrieved and stored for subsequent and facile recombinantproduction of such antibodies.

The antibodies or analogous binding moieties of the invention are usefulfor both prophylaxis and therapy. Thus, they may be used to protect asubject against challenge by the virus as well as for treatment ofsubjects that are already exposed or infected with influenza. Thesubjects of most ultimate interest are human subjects and for use inhuman subjects, human forms or humanized forms of the binding moietieswhich are traditional natural antibodies or immunoreactive fragmentsthereof are preferred. However, the antibodies containing appropriatebinding characteristics as dictated by the CDR regions when used instudies in laboratory animals may retain non-human characteristics. Theantibodies employed in the studies of the examples below, although donein mice, nevertheless contain both variable and constant regions whichare human.

The subjects for which the binding moieties including antibodies of theinvention are useful in therapy and prophylaxis include, in addition tohumans, any subject that is susceptible to infection by flu. Thus,various mammals, such as bovine, porcine, ovine and other mammaliansubjects including horses and household pets will benefit from theprophylactic and therapeutic use of these binding moieties. In addition,influenza is known to infect avian species which will also benefit fromcompositions containing the antibodies of the invention.

Methods of use for prophylaxis and therapy are conventional andgenerally well known. The antibodies or other binding moieties aretypically provided by injection but oral vaccines are also understood tobe effective. Dosage levels and timing of administration are easilyoptimized and within the skill of the art.

Human cells that secrete useful antibodies can be identified using, inparticular, the CellSpot™ method described in U.S. Pat. No. 7,413,868,the contents of which are incorporated herein by reference. Briefly, themethod is able to screen individual cells obtained from human (or other)subjects in high throughput assays taking advantage of labeling withparticulate labels and microscopic observation. In one illustrativeembodiment, even a single cell can be analyzed for antibodies itsecretes by allowing the secreted antibodies to be adsorbed on, orcoupled to, a surface and then treating the surface with desiredantigens each coupled to a distinctive particulate label. The footprintof a cell can therefore be identified with the aid of a microscope.Using this technique, millions of cells can be screened for desirableantibody secretions and even rare antibodies, such as those hereindesirable for passive influenza immunization across strains can berecovered. Since human subjects have existing antibodies to at leastsome influenza strains, and since the antibodies obtained by the methodof the invention bind a conserved sequence, these antibodies serve thepurpose of addressing new strains as well as strains with which humanpopulations have experience.

Methods to obtain suitable antibodies are not limited to the CellSpot™technique, nor are they limited to human subjects. Cells that producesuitable antibodies can be identified by various means and the cells maybe those of laboratory animals such as mice or other rodents. Thenucleic acid sequences encoding these antibodies can be isolated and avariety of forms of antibodies produced, including chimeric andhumanized forms of antibodies produced by non-human cells. In addition,recombinantly produced antibodies or fragments include single-chainantibodies or Fab or Fab₂ regions of them. Human antibodies may also beobtained using hosts such as the XenoMouse® with a humanized immunesystem. Means for production of antibodies for screening for suitablebinding characteristics are well known in the art.

Similarly, means to construct aptamers with desired binding patterns arealso known in the art.

As noted above, antibodies or other binding moieties may bind theactivated form, the inactivated form or both of the hemagglutininprotein. It is advantageous in some instances that the epitope is at thecleavage site of this protein as it is relatively conserved acrossstrains, but preferably the binding moiety binds both the trimer and theactivated form.

The cleavage site for various strains of influenza A and influenza B isknown. For example, the above cited article by Bianchi, et al., shows inTable 1 the sequence around the cleavage site of several such strains:

TABLE 1 Consensus sequence of the solvent-exposedregion of the influenza A and B virus maturational cleavage sites Virus/subtype Strain Sequence^(a) A/H3/HA₀ Consensus NVPEKQTR ↓ GIFGAIAGFIE(SEQ ID  (SEQ ID  NO: 51) NO: 52) A/H1/HA₀ Consensus NIPSIQSR ↓GLFGAIAGFIE (SEQ ID  (SEQ ID  NO: 53) NO: 54) B/HA₀ Consensus^(b) PAKLLKER ↓ GFFGAIAGFLE (SEQ ID  (SEQ ID  NO: 55) NO: 56) ^(a)Theposition of cleavage between HA₁ and HA₂ is indicated by the arrow.^(b)The consensus is the same for both the Victoria and Yamagatalineages.

As indicated, strict consensus occurs starting with the arginine residueupstream of the cleavage site and thus preferred consensus sequencesincluded in the test peptides of the invention have the sequence RGI/L/FFGAIAGFLE (SEQ ID NO:57). It may be possible to use only a portion ofthis sequence in the test peptides.

As noted above, once cells that secrete the desired antibodies have beenidentified, it is straightforward to retrieve the nucleotide sequencesencoding them and to produce the desired antibodies on a large scalerecombinantly. This also enables manipulation of the antibodies so thatthey can be produced, for example, as single-chain antibodies or interms of their variable regions only.

The retrieved nucleic acids may be physically stored and recovered forlater recombinant production and/or the sequence information as to thecoding sequence for the antibody may be retrieved and stored to permitsubsequent synthesis of the appropriate nucleic acids. The availabilityof the information contained in the coding sequences and rapid synthesisand cloning techniques along with known methods of recombinantproduction permits rapid production of needed antibodies in the event ofa pandemic or other emergency.

For reference, the sequences of human constant regions of both heavy andlight chains have been described and are set forth herein as SEQ IDNOS:1-3. In the above-referenced WO2011/160083, various monoclonalantibodies with variable regions of determined amino acid sequence andnucleotide coding sequences have been recovered that bind with varyingdegrees of affinity to HA protein of various strains of influenza. Thestructures of variable regions, both light and heavy chains, of those ofparticular interest herein are set forth for convenience herein as SEQID NOS:22-25. These antibodies include MAB8 and MAB53. MAB53 and MAB8bind with particular affinity to H1; further, MAB53 binds tightly to H5,H7 and H9. MAB8 also binds H7 and H2. Neither of these antibodies bindsstrongly to H3, but MAB579 does bind H3 described herein. H7 and H3 areparticularly attractive targets.

In more detail, each of these MABs binds to at least three differentclades with reasonable or high affinity. MAB53 binds to HA₀ from the H1,H9 and H7 clades and MAB8 binds to HA₀ from H1, H7 clades and lessstrongly to and H3, as demonstrated by ELISA assay against HA₀ protein.The affinities are in the nanomolar range. Reactivity to native trimerof HA from all the Group 1 clades was verified using HA expressed inHEK293 cells with antibody binding measured by flow cytometry.

These results were confirmed using an alternative assay system, thebiolevel interferometry based binding assay designated FortéBio®biosensor. As measured by this more accurate assay, the affinities areas follows:

MAB53/H1=60 pM, H5=6 nM, H7=70 pM, H9=30 pM;

MAB8/H1=9 nM, H3=16 nM, H5=0.2 nM.

The additional specific antibodies identified in the presentapplication, MAB383, MAB486, MAB579, MAB699, MAB700, MAB708, MAB710,MAB711 and MAB723 are represented by SEQ ID NOS:4-21 in terms of theamino acid sequences of their variable heavy chain and light chain.These antibodies bind with enhanced affinity to additional clades ofinfluenza strains. For example, MAB579 binds with high affinity to bothH3 and H7. Thus, these antibodies add to the repertoire of antibodiesuseful in prophylaxis and treatment of influenza.

Multiple technologies now exist for making a single antibody-likemolecule that incorporates antigen specificity domains from two separateantibodies (bi-specific antibody). Thus, a single antibody with verybroad strain reactivity can be constructed using the Fab domains ofindividual antibodies with broad reactivity to Group 1 and Group 2respectively. Suitable technologies have been described by Macrogenics(Rockville, Md.), Micromet (Bethesda, Md.) and Merrimac (Cambridge,Mass.). (See, e.g., Orcutt K D, Ackerman M E, Cieslewicz M, Quiroz E,Slusarczyk A L, Frangioni J V, Wittrup K D. A modular IgG-scFvbispecific antibody topology, Protein Eng Des Sel. (2010) 23:221-228;Fitzgerald J, Lugovskoy A. Rational engineering of antibody therapeuticstargeting multiple oncogene pathways. MAbs. (2011) 1:3(3); Baeuerle P A,Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy.Cancer Res. (2009) 69:4941-4944.)

Thus, it is particularly useful to provide antibodies or other bindingmoieties which bind to multiple types of hemagglutinin protein byconstructing bispecific antibodies. Particularly useful combinations arethose that combine the binding specificity of MAB53 (H1, H5, H9) withMAB579 (H3, H7).

All of the antibodies of the present invention include at least one ofthe binding specificities of the newly disclosed antibodies describedabove. These may be combined with various other antibodies, includingthose that were described in the above-referenced WO2011/160083 as wellas other members of the new group of antibodies disclosed herein. All ofthe possible combinations of such binding specificities are within thescope of the present invention.

While MAB53 binds with high affinity to HA₀, it does not bind HA₁implying binding to the complementary HA₂ fragment, which binding wasconfirmed. As MAB53 does not bind to HA₀ when tested by Western blot, itis assumed that the dominant epitope is at least in part conformational.It was been found that MAB8 and MAB53 bind to the same or nearbyepitopes as demonstrated by their ability to compete with each other forbinding to the HA₀ protein of the H1 clade.

All of the antibodies disclosed herein, including those previouslydisclosed in the above-referenced WO2011/160083 bind to the native HAtrimer expressed on the surface of HA transfected cells. This wasverified using an HA-encoding plasmid provided by S. Galloway and D.Steinhauer of Emory University. That is, the trimer displayed on thecell surface of the clades recognized by the various MAB's of theinvention is recognized by these MAB's.

It was shown that MAB53 and MAB8 differ in that MAB8 is released fromthe HA₀ protein when the pH is lowered to 6, whereas MAB53 is not. Thisdifference is significant as it appears predictive of neutralizingcapability. In tests for the ability to neutralize H1N1 viral infectionin a plaque reduction assay in MDCK target cells, low doses of MAB53 of1-5 μg/ml neutralized infection by H1N1, by H7N3, H5N1 and H9N2.However, MAB8 does not neutralize infection by these strains. Thus,neutralizing strains may be preferentially selected by washing bound MABor fragment at pH 6 during the primary screen, thus removing from HA₀MAB's that are unlikely to remain bound as the antibody-virus complexenters the cell via the endosomal compartment and thus will be expectedto have reduced ability to neutralize the virus. For example, in theCellSpot method HA₀ may be bound to solid support (fluorescent beads)and captured by the MAB or a mixture of MAB's, then washed at pH 6.

It was also shown that mice pretreated with graded doses of MAB53survive challenge with otherwise lethal titers of H1N1 and H5N1 viruseswith 100% protection against H1N1 challenge. The potency is comparableto a prior art antibody described by Crucell which does not showactivity against Group 2 strains. Throsby, M., (supra) 3:e3942. TheCrucell antibodies are heterosubtypic neutralizing monoclonal antibodiescross-protective against H5N1 and H1N1 recovered from human IgM+ memoryB cells. MAB53 also provided full protection at 10 mg/kg; 90% survivedat 2 mg/kg and 50% survived at 0.4 mg/kg. Where challenge by H5N1 wassubstituted for challenge by H1N1, for MAB53, 10 mg/kg gave 80%survival; 2 mg/kg gave 60% survival and 0.4 mg/kg gave 50% survival.

MAB53 and antibodies that bind to the same epitope under the sameconditions, i.e., then remain bound when the pH is lowered to 6, areeffective as passive vaccines suitable for protection of populationsagainst epidemics and pandemics, and for prophylactic or therapeutic useagainst seasonal influenza for patients with a weakened immune system.Combinations of the epitope binding region of MAB53 with the highaffinity binding epitopes of the antibodies of the present invention areparticularly useful in constructing bispecific antibodies. This clearlypermits, for example, effective binding of H7, H3 and H1 in the sameantibody when MAB579 binding regions are included in the antibody. Thisis shown in Table 2 which provides the IC₅₀'s for various strains ofinfluenza hemagglutinin protein shown by MAB579.

TABLE 2 MAB579 IC₅₀ values for various flu strains Subtype Strain IC₅₀(ug/ml) H3 A/Perth/16/2009 0.2 A/Phillipines/2/82 x-79 0.9A/Udorn/307/1976 1.9 A/New York/55/2004* 1.1 A/Wisconsin/67/2005 1.0A/HongKong/68 2.8 A/SW/MN/02719 3.9 H4 A/Bufflehead 15.5 H7A/Canada/rv444/04 1.6 A/Netherlands/219/03 0.6 A/Sanderling/A106-125 >20A/Redknot/NJ/1523470/06 >20 {close oversize brace} BirdViruses A/RuddyTurnstone/A106-892 >20 H10 A/Northern Shoveler 0.8

These values were obtained in the MDCK monolayer microneutralizationassay. A graphical representation of the affinity of MAB579 for variousstrains is also shown in FIG. 2. As shown, while H3 and H7 are tightlybound, negligible binding affinity is found for H1. Thus, it isparticularly advantageous to combine the binding region of MAB579 withthat of an MAB with high binding to H1. In this case, then, both Group 1and Group 2 are represented. One embodiment of the invention includes abiospecific antibody that binds both the epitope bound by MAB53 and thatbound by MAB579.

In addition to bispecific antibodies per se, the invention contemplatesthe use of the heavy chain only in constructs for neutralization ofviral infection; such antibodies may also be bispecific. It isunderstood in the art that specificity is mostly conferred by the heavychain variable regions, and in some stances, heavy chains alone havebeen successful as active ingredients in vaccines. Alternatively, theheavy chain of appropriate specificity may be associated with variousforms of light chain to enhance the affinity or ability to neutralizevirus.

It is particularly noted that the CDR3 region of the heavy chains of theantibodies described herein is extended and contains multiple tyrosineresidues. It is understood that such tyrosine residues may be sulfonatedas a posttranslational event. Thus, also part of the invention arevaccines which comprise the CDR3 regions of the heavy chains of MAB579,MAB699, MAB700, MAB708, MAB710, MAB711 or MAB723 wherein one or more ofthe tyrosine residues in said region is optionally sulfonated. Theseregions with or without sulfonation may also be used alone as passivevaccines. The sulfonation of the CDR3 region is consistent with criteriafor sulfonation as described by Monigatti, F., et al., Bioinformatics(2002) 18:769-770. Other instances where CDR3 regions of heavy chainshave been used successfully alone in neutralization of viral infectionare described in Pejchal, R., et al., PNAS (2010) 107:11483-11488 and byLiu, L., et al., J. Virol. (2011) 85:8467-8476.

As used herein, the term “antibody” includes immunoreactive fragments oftraditional antibodies even if, on occasion, “fragments” are mentionedredundantly. The antibodies, thus, include Fab fragments, F_(v)single-chain antibodies which contain a substantially only variableregions, bispecific antibodies and their various fragmented forms thatstill retain immunospecificity and proteins in general that mimic theactivity of “natural” antibodies by comprising amino acid sequences ormodified amino acid sequences (i.e., pseudopeptides) that approximatethe activity of variable regions of more traditional naturally occurringantibodies.

Antibody Structures

These are presented in the following order:

1. Amino acid sequences of the constant region of human IgG1 heavychain, human constant kappa and human constant lambda;

2. Heavy and light chain amino acid sequences of the variable regions ofthe heavy and light chains of MAB 383, 486, 579, 699, 700,708, 710, 711and 723 (The CDR regions are underlined in MAB's 579, 699, 700, 708,710, 711 and 723.);

3. Heavy and light chain variable region amino acid sequences of MAB8and MAB53 described in WO2011/160083 (The LC sequences shown in '083also contained constant region and this has been deleted.);

4. Nucleotide sequences encoding the constant region of human IgG1 heavychain, human constant kappa and human constant lambda;

5. Nucleotide sequences encoding heavy and light chain amino acidsequences of the variable regions of the heavy and light chains of MAB383, 486, 579, 699, 700,708, 710, 711 and 723;

6. Nucleotide sequences encoding heavy and light chain variable regionamino acid sequences of MAB8 and MAB53.

With respect to the indicated CDR regions, it should be noted that thereis more than one system for identifying CDRs. Most frequently used isthe Kabat system originally set forth in Wu, T. T., et al., J. Exp. Med.(1970) 132:211-250. Kabat is a widely adopted system which identifiesspecific positions as associated with CDRs. An additional system, theChothia numbering scheme provides slightly different results. It isdescribed in Al-Lazikani, B., et al., J. Molec. Biol. (1997)273:927-948. Depending on which system is used, slightly differentresults for CDRs are indicated. For example, in MAB53 the heavy chainCDR according to Kabat is KYAIN whereas the Clothia system designatesGGIIRKYAIN. The heavy chain CDR2 region has an additional G at theN-terminus and the CDR3 an additional AR at the N-terminus. For thelight chain, the CDR designations are identical in both systems.

Some criticism has been leveled at both systems by various workers;therefore, it is understood that the CDR regions as designated hereinand in the claims may vary slightly. As long as the resulting variableregions retain their binding ability, the precise location of the CDRregions is not significant, and those regions designated in the claimsare to be considered to include CDRs identified by any accepted system.

Human IgG1 HC amino acid sequence of  constant region (SEQ ID NO: 1)ASTKGPSVFPLVPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Human LC amino acid sequence of constant kappa region (SEQ ID NO: 2)RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTK SFNRGECHuman LC amino acid sequence of constant  lambda region (SEQ ID NO: 3)GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTV VPAECSMAB383 HC Amino acid sequence of variable domain (SEQ ID NO: 4)QVQLVQSGAEVKRPGASVKVSCRASGYTFTSFGFSWVRQAPGQGLEWMGWISAYNGDTKSPQKLQGRVTMTTDTSTNTAYMELRSLISDDTAVYYCARAPPLYYSSWSSDYWGQGTLLTVSS MAB383 LC Amino acid sequence of variable domain(SEQ ID NO: 5) DIQMTQSPGTLSLSPGERATLSCRASQSVSSNYLAWYQQKHGQAPRPLIYGASRRATDVPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRTFG QGTKLEIKMAB486 HC Amino acid sequence of variable domain (SEQ ID NO: 6)QVQLVESGGGMVQPGGSRRLSCAASGFSFSTYGMHWVRQAPGKGLEWVAVISYDGEKQYYLDSVKGRFTISRDNSKDTLYLQMNSLTAEDTAVYYCVKESARRLLRYFEWLLSSPFDNWGQGALVTVSSMAB486 LC Amino acid sequence of variable domain (SEQ ID NO: 7)DIVMTQSPDSLAVSLGERATINCKSSQTVLYTSNKKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTS PYTFGQGTKLEIKMAB579 HC Amino acid sequence of variable domain (SEQ ID NO: 8)QVQLVQSGAEVKKPGASVKVSCKTSGYTFTAYTIHWVRQAPGQRLEWMGWINAGNGHTKYSQRFKGRVTITRDTSARTTYMELRSLTSEDTALYFCARGPETYYYDKTNWLNSHPDEYFQHWGHGTQVTVSSMAB579 LC Amino acid sequence of variable domain (SEQ ID NO: 9)DIQMTQSPSTLSASVGDRVTITCRASQTINNYLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQEYNNDSPLTFG GGTKVEIKMAB699 HC Amino acid sequence of variable domain (SEQ ID NO: 10)QLQLVQSGAEVKKPGASVKLSCKASGYTFTSYTLHWVRQAPGQTLEWMGWINAGNGKTKYPPKFRGRVTITRDTSATTVDMHLSSLTSEDTAVYFCARGPESYYYDRSDWLNSHPDEYFQYWGQGTLVIVSSMAB699 LC Amino acid sequence of variable domain (SEQ ID NO: 11)DIQMTQSPSTLSASVGDRVTIACRASQSISSWLAWYQQKPGKAPKLLIYKASQLESGVPSRFSGSGSGTEFTLTINSLQPDDFATYYCQLYNVYSPLTFG GGTRVDIKMAB700 HC Amino acid sequence of variable domain (SEQ ID NO: 12)QVQLVESGADVKKPGASVTVSCKASGYTFRSFTMHWVRQVPGQRLEWMGWINAGNGKTKYSQKFQGRVIVTRDTSASTAYMELSSLTSEDTAVYYCARGPETYYYDSSNWLNSHPDEYLQYWGQGTPVTVSSMAB700 LC Amino acid sequence of variable domain (SEQ ID NO: 13)DIVLTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQEYNNNSPLTFG GGTKVEIKMAB708 HC Amino acid sequence of variable domain (SEQ ID NO: 14)QVQLVQSGADVKRPGASVTVSCKASGYTFRSFTMHWVRQVPGQRLEWMGWINAGNGKTKYSQKFQGRVIVTRDTSANTAYMELSSLTSEDTAVYYCARGPETYYYDSSNWLNSHPDEYFQHWGQGTPVTVSSMAB708 LC Amino acid sequence of variable domain (SEQ ID NO: 15)DIQMTQSPSTLPASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQEYNNNSPLTFG GGTKVEIKMAB710 HC Amino acid sequence of variable domain (SEQ ID NO: 16)QVQLQESGAEVKKPGASVQVSCKASGYTFTSYSVHWVRQAPGQRPEWMGWINAGNGKTKYPQKFKGRVTITRDTLARTVNIHLSSLTSEDTAVYFCARGPDSYYYDRNDWLNSHPDEYFQHWGQGTVVIVSSMAB710 LC Amino acid sequence of variable domain (SEQ ID NO: 17)DIVMTQSPSTLSASVGDRVTISCRASQSIDSWLAWYQQKPGKAPKLLIYKASNLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQLYNVHLITFGG GTRVDIKMAB711 HC Amino acid sequence of variable domain (SEQ ID NO: 18)QVQLVESGAEVKKPGASVKITCEASGYTFNTYTIHWLRQAPGQRLEWMGWINAANGHTKYSRKLRSRVTIKRDTSARTSYMELSSLGSEDTAVYYCARGPETYYFDKTNWLNSHPDEYFQHWGQGTLVTVSSMAB711 LC Amino acid sequence of variable domain (SEQ ID NO: 19)DIVMTQSPSTLSASVGDRVTITCRASQSISTWLAWYQQKPGKAPKLLIYKASNLESGVPARFSGSGSGTEFTLTISSLQPDDFATYYCQEYNNDSPLILG GGTTVEIKMAB723 HC Amino acid sequence of variable domain (SEQ ID NO: 20)QVQLVQSGAAVNKPGASVKVSCKASGYSFTSYTLHWVRQAPGQRPEWIGWINAGNGKVKYPRKLQGRITITRDVSATTVHMELRSLTSEDTGLYYCARGPESYFFDTSNHLNSHPDEYFQFWGQGTLVTVSSMAB723 LC Amino acid sequence of variable domain (SEQ ID NO: 21)DIQMTQSPSTLSASVGDRVTITCRASQSISSYLAWYQQKPGKAPKLLIYKASNLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQEYNNNSPLTFG AGTKVEIKMAB8 HC amino acid sequence of variable domain (SEQ ID NO: 22)EVQLVESGGGLVKPGGSLRLSCAASGFTFSTYTMSWVRQAPGQGLEWVSSITRTSSNIYYADSVEGRFTISRDNAKNSLYLQMHSLRVEDTAVYYCARIS GVVGPVPFDYWGQGTLITVSSMAB8 LC amino acid sequence (SEQ ID NO: 23)DIQMTQSPSSLSASVGDRVTITCRASQTISKYLNWYQQKPGRAPKLLIYSASSLQSGVPSRFTGSGSGTDFTLTITSLQPEDFATYYCQQSYRPSQITFG PGTKVDIKMAB53 HC amino acid sequence of variable domain (SEQ ID NO: 24)QVQLVQSGAEVRKPGSSVKVSCKVSGGIIRKYAINWVRQAPGQGLEWMGGIIAIFNTANYAQKFQGRVTITADESTSTVYMELSSLRSEDTALYYCARGM NYYSDYFDYWGQGSLVTVSPMAB53 LC amino acid sequence (SEQ ID NO: 25)EIVLTQSPGTLSLSPGERATLSCRASQSVRSNNLAWYQHKPGQAPRLLIFGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPALTF GGGTKVEIKHuman IgG1 HC nucleotide sequence of constant region  (introns are underlined) (SEQ ID NO: 26)GCCTCCACCAAGGGCCCATCAGTCTTCCCCCTGGCACCCTCTACCAAGAGCACCTCTGGGGGCACAACGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGGTGAGAGGCCAGCACAGGGAGGGAGGGTGTCTGCTGGAAGCCAGGCTCAGCGCTCCTGCCTGGACGCATCCCGGCTATGCAGTCCCAGTCCAGGGCAGCAAGGCAGGCCCCGTCTGCCTCTTCACCCGGAGGCCTCTGCCCGCCCCACTCATGCTCAGGGAGAGGGTCTTCTGGCTTTTTCCCCAGGCTCTGGGCAGGCACAGGCTAGGTGCCCCTAACCCAGGCCCTGCACACAAAGGGGCAGGTGCTGGGCTCAGACCTGCCAAGAGCCATATCCGGGAGGACCCTGCCCCTGACCTAAGCCCACCCCAAAGGCCAAACTCTCCACTCCCTCAGCTCGGACACCTTCTCTCCTCCCAGATTCCAGTAACTCCCAATCTTCTCTCTGCAGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGGTAAGCCAGCCCAGGCCTCGCCCTCCAGCTCAAGGCGGGACAGGTGCCCTAGAGTAGCCTGCATCCAGGGACAGGCCCCAGCCGGGTGCTGACACGTCCACCTCCATCTCTTCCTCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGTGGGACCCGTGGGGTGCGAGGGCCACATGGACAGAGGCCGGCTCGGCCCACCCTCTGCCCTGAGAGTGACCGCTGTACCAACCTCTGTCCCTACAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGAHuman LC nucleotide sequence of constant  kappa region (SEQ ID NO: 27)CGAACTGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCTAGCGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTTAG Human LC nucleotide sequence of constant lambda region (SEQ ID NO: 28)GGTCAGCCCAAGGCTGCCCCCTCTGTCACTCTGTTCCCGCCCTCTAGCGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTG GTCCCTGCAGAATGCTCTMAB383 HC Nucleotide sequence of variable domain (SEQ ID NO: 29)CAGGTGCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAGGCCTGGGGCCTCAGTGAAGGTCTCCTGCAGGGCTTCTGGTTACACCTTTACTAGCTTCGGTTTCAGCTGGGTGCGACAGGCCCCAGGACAAGGGCTTGAGTGGATGGGGTGGATCAGCGCTTACAATGGTGACACAAAGTCTCCACAGAAGCTCCAGGGCAGAGTCACCATGACTACAGACACATCCACGAACACAGCCTACATGGAGCTGAGGAGCCTCATATCTGACGACACGGCCGTGTATTATTGTGCGAGAGCCCCCCCCCTGTATTACAGTAGCTGGTCCTCAGACTACTGGGGCCAGGGAACCCT GCTCACCGTCTCCTCAMAB383 LC Nucleotide sequence of variable domain (SEQ ID NO: 30)GATATCCAGATGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTCAGTAGCAACTACTTAGCCTGGTACCAGCAGAAACATGGCCAGGCTCCCAGGCCCCTCATCTACGGTGCATCCAGAAGGGCCACTGACGTCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAACCTGAAGATTTTGCAGTGTATTATTGTCAGCAGTATGGTAGTTCACCTCGAACTTTTGGCCAGGGGACCAAACTGGAAATCAAACMAB486 HC Nucleotide sequence of variable domain (SEQ ID NO: 31)CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCATGGTCCAGCCGGGGGGGTCCCGGAGACTCTCCTGTGCAGCCTCTGGATTCAGCTTCAGTACCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATTTCATATGATGGAGAAAAGCAATATTATCTAGACTCCGTGAAGGGACGATTCACCATCTCCAGAGACAATTCCAAGGACACCCTCTATCTGCAAATGAACAGTCTGACAGCTGAGGACACGGCTGTGTATTACTGTGTGAAGGAATCAGCGCGTCGATTATTACGATATTTTGAGTGGTTATTAAGTTCGCCTTTTGACAACTGGGGCCAGGGAGCCCTAGTCACCGTCTCCTCAMAB486 LC Nucleotide sequence of variable domain (SEQ ID NO: 32)GATATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTTTGGGCGAGAGGGCCACCATCAACTGCAAGTCCAGCCAGACTGTTTTATACACCTCCAACAAGAAAAATTACTTAGCCTGGTACCAACAGAAGCCAGGGCAGCCTCCTAAACTGCTCATTTACTGGGCATCTACCCGGGAATCCGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGGCTGAGGATGTGGCAGTTTATTACTGTCAGCAATATTATACGTCTCCCTACACATTTGGCCAGGGGACCAAGCTGGAGATCAAAMAB579 HC Nucleotide sequence of variable domain (SEQ ID NO: 33)CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGACTTCTGGATACACCTTCACAGCCTATACTATACACTGGGTGCGCCAGGCCCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTCACACGAAATATTCACAGAGGTTCAAGGGCAGAGTCACCATTACCAGGGACACATCCGCGAGGACAACCTACATGGAGCTGCGCAGTCTGACATCTGAGGACACGGCTCTATATTTCTGTGCGAGAGGGCCCGAGACATATTATTATGATAAAACCAATTGGCTGAACTCCCATCCAGATGAATACTTCCAGCACTGGGGCCACGGCACCCAGGTCACCGTCTCCTCAMAB579 LC Nucleotide sequence of variable domain (SEQ ID NO: 34)GATATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCCAGTCAGACTATTAATAACTACTTGGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAACTCCTGATCTATAAGGCGTCTAGTTTAGAAAGTGGGGTCCCATCAAGATTCAGTGGCAGTGGGTCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAGAATATAATAATGATTCTCCCCTAACTTTCGGCGGAGGGACCAAAGTGGAGATCAAAMAB699 HC Nucleotide sequence of variable domain (SEQ ID NO: 35)CAGGTGCAGCTGGTGCAGTCCGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGCTTTCCTGCAAGGCTTCTGGGTACACCTTCACTTCCTATACTCTACATTGGGTGCGCCAGGCCCCCGGACAGACACTTGAGTGGATGGGATGGATCAACGCTGGCAACGGTAAAACAAAATATCCACCGAAGTTCAGGGGCAGAGTCACCATTACCAGGGACACGTCCGCGACCACAGTCGACATGCATCTAAGCAGCCTGACATCTGAAGACACGGCTGTGTATTTCTGTGCGAGAGGGCCCGAAAGTTATTACTATGATAGAAGTGATTGGCTGAACTCCCATCCAGATGAATACTTCCAGTACTGGGGCCAGGGCACCCTGGTCATCGTCTCCTCAMAB699 LC Nucleotide sequence of variable domain (SEQ ID NO: 36)GATATCGTGCTGACGCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGGGACAGAGTCACCATCGCTTGCCGGGCCAGTCAGAGTATTAGCAGCTGGCTGGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAACTCCTGATCTACAAGGCGTCTCAGTTAGAAAGTGGGGTCCCATCAAGATTCAGCGGCAGCGGATCTGGGACAGAGTTCACTCTCACCATCAACAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAACTTTATAATGTTTATTCTCCGCTCACTTTCGGCGGGGGGACCAGGGTGGACATCAAAMAB700 HC Nucleotide sequence of variable domain (SEQ ID NO: 37)CAGGTGCAGCTGGTGGAGTCTGGGGCTGACGTGAAGAAGCCTGGGGCCTCAGTGACGGTTTCCTGCAAGGCCTCAGGATACACCTTCAGGAGTTTTACTATGCATTGGGTGCGCCAGGTCCCCGGACAAAGGCTTGAGTGGATGGGATGGATCAACGCTGGCAATGGTAAAACAAAGTATTCTCAGAAGTTCCAGGGCAGAGTCATCGTTACCAGGGACACATCCGCGAGCACAGCCTACATGGAGCTGAGCAGCCTAACATCTGAAGACACGGCTGTTTATTACTGTGCGAGAGGGCCCGAAACATATTACTATGATAGTAGTAATTGGCTGAATTCCCATCCAGATGAATATCTCCAGTACTGGGGCCAGGGCACCCCGGTCACCGTCTCCTCAMAB700 LC Nucleotide sequence of variable domain (SEQ ID NO: 38)GATATCCAGATGACCCAGTCTCCTTCCACCCTGTCTGCGTCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCCAGTCAGAGTATTAGTAGCTGGTTGGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAACTCCTGATCTATAAGGCGTCTACTTTAGAAAGTGGGGTCCCATCCAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAGAGTATAATAATAATTCTCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAMAB708 HC Nucleotide sequence of variable domain (SEQ ID NO: 39)CAGGTGCAGCTGGTGCAGTCTGGGGCTGACGTGAAGAGGCCTGGGGCCTCAGTGACGGTTTCCTGCAAGGCTTCAGGATACACCTTCAGGAGCTTTACTATGCATTGGGTGCGCCAGGTCCCCGGACAAAGGCTGGAGTGGATGGGATGGATCAACGCTGGCAATGGTAAAACAAAATATTCCCAGAAGTTTCAGGGCAGAGTCATCGTTACCAGGGACACATCCGCGAACACGGCCTACATGGAGCTGAGCAGCCTGACATCTGAAGACACGGCTGTTTATTACTGTGCGAGAGGGCCCGAAACATATTATTATGATAGTAGTAATTGGCTGAACTCCCATCCAGATGA ATATTTCCAGCACTGGMAB708 LC Nucleotide sequence of variable domain (SEQ ID NO: 40)GATATCCAGATGACCCAGTCTCCTTCCACCCTGCCTGCGTCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCCAGTCAGAGTATTAGTAGCTGGTTGGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAACTTCTGATCTATAAGGCGTCTAGTTTAGAAAGTGGGGTCCCATCCAGGTTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAGGAGTATAATAATAATTCTCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAMAB710 HC Nucleotide sequence of variable domain (SEQ ID NO: 41)CAAGTGCAGCTGCAGGAGTCGGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGCAGGTTTCCTGCAAGGCTTCTGGGTACACCTTCACGTCCTATAGCGTACATTGGGTGCGCCAGGCCCCCGGACAAAGGCCTGAGTGGATGGGATGGATCAACGCTGGCAACGGAAAGACAAAATATCCACAGAAGTTCAAGGGCAGAGTCACCATAACCAGAGACACATTAGCGCGCACTGTCAACATACATCTAAGCAGCCTGACATCCGAAGACACGGCTGTGTATTTCTGTGCGAGAGGGCCCGATAGTTATTACTATGATAGAAATGATTGGCTGAACTCCCATCCAGATGAATACTTCCAGCACTGGGGCCAGGGCACCGTGGTCATCGTCTCCTCAMAB710 LC Nucleotide sequence of variable domain (SEQ ID NO: 42)GATATCGTGATGACCCAGTCTCCTTCCACCCTGTCTGCATCTGTGGGAGACAGAGTCACCATCTCTTGCCGGGCCAGTCAGAGTATTGACAGTTGGTTGGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAACTCCTGATCTATAAGGCGTCTAATTTAGAAAGTGGGGTCCCATCAAGATTCAGCGGCAGCGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCGACTTATTACTGCCAACTCTATAATGTTCATTTGATCACTTTCGGCGGA GGGACCAGGGTGGACATCAAAMAB711 HC Nucleotide sequence of variable domain (SEQ ID NO: 43)CAGGTGCAGCTGGTGGAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGATCACCTGCGAGGCTTCTGGATACACTTTCAATACCTATACTATACATTGGCTGCGCCAGGCCCCCGGACAAAGACTTGAGTGGATGGGGTGGATCAACGCTGCCAATGGTCATACAAAATATTCACGGAAGCTCAGGTCCAGAGTCACCATTAAGAGGGACACATCCGCGAGGACAAGTTACATGGAGCTGAGCAGCCTGGGATCTGAAGACACGGCTGTCTATTACTGTGCGAGAGGGCCCGAAACATATTACTTTGATAAGACGAATTGGCTGAACTCCCATCCAGATGAATACTTCCAGCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAMAB711 LC Nucleotide sequence of variable domain (SEQ ID NO: 44)GATATCGTGATGACGCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCCAGTCAGAGTATTTCTACCTGGTTGGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAAGGCGTCCAATTTAGAAAGTGGGGTCCCAGCAAGATTCAGCGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTACTGCCAAGAATATAATAATGATTCTCCGCTGATTTTAGGCGGAGGGACCACGGTGGAGATCAAAMAB723 HC Nucleotide sequence of variable domain (SEQ ID NO: 45)CAGGTGCAGCTGGTGCAGTCTGGGGCTGCGGTGAACAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCTTCTGGATACAGCTTCACTAGTTACACTTTGCATTGGGTGCGCCAGGCCCCCGGACAAAGGCCTGAGTGGATAGGGTGGATCAACGCTGGCAATGGTAAAGTAAAATATCCACGGAAGTTGCAGGGCAGAATCACCATAACCAGGGACGTATCCGCTACGACAGTTCACATGGAACTGAGGAGCCTGACATCTGAGGACACGGGTCTATATTACTGTGCGAGAGGGCCCGAAAGTTACTTCTTTGATACTTCTAATCATCTGAACTCCCATCCAGATGAATACTTCCAGTTCTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAMAB723 LC Nucleotide sequence of variable domain (SEQ ID NO: 46)GATATCGTGCTGACGCAGTCTCCTTCCACCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCCAGTCAGAGTATTAGTAGTTACTTGGCCTGGTATCAACAGAAACCAGGGAAAGCCCCTAAACTCCTGATCTATAAGGCGTCTAATTTAGAAAGTGGGGTCCCATCAAGATTCAGCGGCAGTGGATCTGGGACAGAATTCACTCTCACCATCAGCAGCCTGCAGCCTGATGATTTTGCAACTTATTATTGCCAAGAATATAATAATAACTCTCCGCTCACTTTCGGCGCAGGGACCAAGGTGGAGATCAAA MAB8 HC variable domain nucleotide sequence(SEQ ID NO: 47) GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGTTTCACTTTCAGTACCTATACTATGAGTTGGGTCCGCCAGGCTCCAGGGCAGGGGCTAGAGTGGGTCTCGTCCATTACTAGGACTAGTAGTAATATATACTACGCAGACTCAGTGGAGGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTATCTGCAGATGCATAGCCTGAGAGTCGAAGACACGGCTGTGTATTACTGTGCGAGAATCAGCGGGGTAGTGGGACCTGTCCCCTTTGACTACTGGGGCCAGGGAACCCTGAT CACCGTCTCCTCTMAB8 LC variable domain nucleotide sequence (SEQ ID NO: 48)GACATCCAGATGACCCAGTCTCCATCTTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCAAGTCAGACCATTAGCAAGTATTTAAATTGGTATCAGCAGAAGCCAGGGAGAGCCCCTAAACTCCTGATCTACTCTGCGTCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCACTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCACCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTTACAGACCCTCCCAGATCACTTTCGGCCCTGGGACCAAAGTGGATATCAAA MAB53 HC variable domain nucleotide sequence(SEQ ID NO: 49) CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAGGAAGCCGGGGTCCTCGGTGAAGGTCTCCTGCAAGGTTTCTGGAGGCATCATTAGGAAATATGCTATCAACTGGGTGCGACAGGCCCCCGGACAAGGGCTTGAGTGGATGGGAGGGATCATCGCTATCTTTAATACAGCAAACTATGCACAGAAATTCCAGGGCAGAGTCACGATTACCGCGGACGAGTCCACGAGCACAGTCTACATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCCCTTTATTACTGTGCGAGAGGAATGAATTACTACAGTGACTACTTTGACTACTGGGGCCAGGGAAGCCTTGTCAC CGTCTCCCCAMAB53 LC variable domain nucleotide sequence (SEQ ID NO: 50)GAAATTGTGTTGACACAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGAAGCAACAACTTAGCCTGGTACCAGCACAAACCTGGCCAGGCTCCCAGGCTCCTCATCTTTGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTATATTACTGTCAGCAGTATGGTAGCTCACCTGCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAA

The following examples are offered to illustrate but not to limit theinvention.

EXAMPLE 1 Affinity of MAB53 and MAB579

The affinity of MAB53 was reported in the above cited PCT publication.This antibody binds HA strongly from clades H5, H7, H1 and H9, with lessaffinity for H2 and H3. MAB579 binds HA with high affinity with respectto H7 and H3. FIGS. 3A and 3B show typical results using the standardFortéBio™ assay for each antibody.

EXAMPLE 2 Neutralization of Infection by MAB486 and MAB579

MAB's 486 and 579 were tested for inhibition of infection by H1N1 andH3N2 (A/Perth/16/2009) and plaque formation in MDCK cell monolayers inthe presence or absence of trypsin in the initial infection phase.MAB486 and pAb xCP (a rabbit polyclonal raised against the cleavage siteconsensus sequence) neutralize H1N1 (A/California/04/2009) only in theabsence of trypsin as shown in FIG. 4A, and are unable to inhibitinfection and plaque formation if the virus is first activated withtrypsin. This shows that antibodies directed to the fusion region withepitopes relying on intact fusion peptide (i.e., protease susceptible)are not as effective in controlling viral infection. As shown in FIG.4B, MAB579 inhibits infection in both the presence and absence oftrypsin.

The ability of MAB53 to neutralize infection was previously reported,but a comparison of the affinities and EC₅₀ for in vitro neutralizationare compared to those for the Crucell monoclonal antibodies CR6261 inTable 3 below.

TABLE 3 Potency in vitro of Trellis mAbs vs. mAbs cloned from Crucellpatents MAB53 MAB53 “CR6261” Potency Strain K_(D) (nM) EC₅₀ (μg/mL) EC₅₀(μg/mL) Difference H1N1 A/CA/07/09 0.1 0.14 4.0 30x H5N1 A/VN/1204 0.50.10 3.7 40x H2N2 A/Mallard/MN/2008 nd 1.20 nd H9N2 Mallard/MN/98 nd0.10 nd MAB579 MAB579 “CR8020” Potency Strain KD (nM) EC₅₀ (μg/mL) EC₅₀(μg/mL) Difference H3N2 A/Wisconsin/67/2005 nd 1.0 3.5  3x H3N2A/Perth/16/2009 0.8 0.05 2.0 40x H3N2 A/New York/55/2004 0.2 2.0 10.0 5x H3N2 A/Hong Kong/8/68 0.2 2.0 7.6  3x H7N7 A/Netherlands/219/03 0.40.7 13.1 20x H7N3 A/Canada/rv444/04 0.6 0.5 nd H4N4 A/Bufflehead nd15.0 >40  3x H10N7 A/Northern Shoveler nd 0.8 nd

The values for EC₅₀ were obtained as described above.

EXAMPLE 3 Determination of Epitopes

Pepscan CLIPS™ Technology was used to map the binding sites of MAB53 andMAB579. About 6,000 unique peptides of varying lengths and with varyinglength connecters to constrain the ends of each peptide to mimic nativestructure were synthesized for H1 and for H3. Binding to the stalkregion by MAB53 and MAB579 was confirmed using rabbit sera to globularhead or stalk as competitors and by direct binding to peptides from thestalk region. As noted above, MAB486 binds both Group 1 and Group 2 butonly in the preactivated state before protease cleavage of HA₀ todisulfide linked HA₁ and HA₂. It was concluded that the epitope forcross-clade binding is a discontinuous epitope spanning two monomers ofthe native trimeric HA₀.

EXAMPLE 4 In Vivo Potency (MAB53) and Pharmacokinetics (MAB53 andMAB579)

The strains used in these experiments were:

H1N1: A/CA/04/09;

H5N1: A/Vietnam/1203/04/HPAI;

H3N2: A/Perth/16/09;

H7N3: A/Red Knot/NJ/1523470/06.

To test prophylaxis, MAB53 was provided to mice as a singleintraperitoneal dose of 10 mg/kg at Day −1 which was followed at Day 0by a dose of virus 10 times the LD₅₀ delivered intranasally. The potencyof MAB53 was determined to exhibit EC₅₀ at 0.4 mg/kg as compared to theCrucell antibody CR6261 which is reported to exhibit an EC₅₀ of 1-1.5mg/kg (Koudstaal, W., et al., J. Infect. Dis. (2009) 200:1870-1873).

To test therapeutic effectiveness, MAB was given as a singleintraperitoneal dose of 10 mg/kg at Day +3 for most strains or at Day +1for H7N3. MAB53 was fully effective with respect to H1N1 and H5N1whereas essentially all control mice were dead by Day 10. MAB579 wasessentially fully effective against H3N2 and H7N3 whereas virtually allcontrol mice were dead before Day 10.

Weight loss was also measured and declines were no worse than 20% in thetreated mice.

In comparison to treatment with Tamiflu® (oseltamivir phosphate), mice(10 per group) were anesthetized and infected intranasally with 10 timesthe LD₅₀ dose of virus (H1N1 Influenza A/Ca/04/09). MAB53 (or controlisotype-matched human IgG) was given i.p. at Day +1 post-infection.Tamiflu® was given by oral gavage twice daily for 4 days starting on Day+1 post-infection. Both mortality and morbidity (assessed by weightloss) were far more severe for the Tamiflu® cohort compared to the MAB53cohort.

For controls, all of the mice were dead by eight days post infection.For those treated with Tamiflu®, all but two mice were dead before eightdays post infection; these two mice survived at least to Day 14. In thegroup treated with MAB53, eight of the ten mice survived past Day 8 toDay 14.

With respect to weight loss, the control group declined in weight to 70%of their initial weight after eight days. The declines in weight werereversed at Day 4 for the mice treated with MAB53 and the originalweight was exceeded by Day 14. In the Tamiflu® treated mice, weight losswas reversed by Day 6 but only 92% of the original weight was attainedby Day 14.

Pharmacokinetics were also examined in mice for MAB53 and MAB579. Theseshow a half-life in mice of about 7-14 days corresponding to a half-lifein humans of 3-4 weeks. This corresponds to that typical for an IgG1 κMAB. The bispecific antibody MAB579/53Bi (see Example 5) shows a similarhalf-life.

EXAMPLE 5 Construction of MAB579/53Bi

The construction of MAB579/53Bi provides an scFv portion of MAB53coupled to the constant region of MAB579 as shown in FIG. 5.Construction of such bispecific antibodies is well known in the art(Marvin, J. S., Acta Pharmacologica Sinica (2005) 26:649-658). Thus,MAB579/53Bi provides bivalent binding at both ends of the molecule alongwith an intact Fc region. Table 4 shows that the bispecific antibodyretains the affinity of the independent antibodies as measured byFortéBio™ in nM. The bispecific antibody further retains theneutralization capability of the individual antibodies of which it iscomposed and has an EC₅₀ of 3.5 μg/ml against H1N1; 6.0 μg/ml againstH5N1, and 2.2 μg/ml against H3N2.

TABLE 4 Affinity by FortéBio ™ (nM) Strain MAB53 MAB579 Bi-Specific H1Calif/07/09 0.2 0.3 H5 Vietnam/1203/2004 0.5 2.5 H3 HongKong/8/1968 0.20.2 H3 Perth 16/09 0.7 1.3 H7 Netherlands/219/03 0.4 0.3

EXAMPLE 6 In Vivo Potency of MAB579/53Bi

In vivo efficacy was measured as described generally in Example 4 withthe results as shown in FIGS. 6A-6E.

As shown in FIGS. 6A and 6C, mice were infected with A/Ca/04/09 (H1N1)(representing influenza Group 1) on Day 0, and treated by IP injectionwith 10 mg/ml MAB53 alone, 10 mg/ml MAB579 alone or either a mixture ofMAB53 and MAB579 (FIG. 6A) or the bispecific antibody (FIG. 6C) at Day2, (FIG. 6C also shows weight loss curves). Controls received IgG at 20mg/kg. The mixture of MAB's was administered at 10 mg/kg each and thebispecific antibody was administered at 10 mg/kg. As shown in FIG. 6A,the mixture of MAB53 and MAB579, as well as MAB53 alone, wereprotective, while MAB579 and control resulted in no survivors after 10days. As shown in FIG. 6C, the bispecific antibody was equally effectiveas the mixture.

Similar results were obtained in the analogous protocol for miceinfected with a Group 2 representative Philippines 2/82 (H2N3) as shownin FIGS. 6B and 6D. (FIG. 6D also shows weight loss curves.) As shown inFIG. 6B, the mixture was effective against this virus as was MAB579, butMAB53 alone and control resulted in death after 10 days. In FIG. 6D, itis demonstrated that the bispecific antibody is equally effective as themixture.

FIG. 6E shows the results of treatment of infection using the analogousprotocol where the challenge was with both Group 1 and Group 2representatives H1N1 and H2N3 which both infected the same mouse. Acombination of MAB579 and MAB53 each at 3 mg/kg was completelyprotective and at 1 mg/kg each protected 80% of the mice. This issignificant because co-infection occurs in nature resulting inrecombined virus that may cause a pandemic.

1. A monoclonal antibody including a bi-specific antibody orimmunoreactive fragment thereof, which antibody or fragment binds to thesame epitope of influenza A virus as does MAB383, MAB486, MAB579,MAB699, MAB700, MAB708, MAB710, MAB711 or MAB723; and that neutralizesinfection by H3 and H7; and which is human or humanized.
 2. (canceled)3. The antibody or fragment of claim 1 that binds to the same epitope asMAB579; and to the same epitope as MAB53. 4-5. (canceled)
 6. Theantibody or fragment of claim 1 which is comprises a heavy chaincomprising the sequence a) QVQLVQSGAEVKRPGASVKVSCRASGYTFTSFGFSWVRQAPGQGLEWMGWISAYNGDTKSPQKLQGRVTMTTDTSTNTAYMELRSLISDDTAVYYCARAPPLYYSSWSSDYWGQGTLLTV SS (MAB383) or b)QVQLVESGGGMVQPGGSRRLSCAASGFSFSTYGMHWVRQAPGKGLEWVAVISYDGEKQYYLDSVKGRFTISRDNSKDTLYLQMNSLTAEDTAVYYCVKESARRLLRYFEWLLSSPFDNWG QGALVTVSS (MAB486) or c)QVQLVQSGAEVKKPGASVKVSCKTSGYTFTAYTIHWVRQAPGQRLEWMGWINAGNGHTKYSQRFKGRVTITRDTSARTTYMELRSLTSEDTALYFCARGPETYYYDKTNWLNSHPDEYFQ HWGHGTQVTVSS (MAB579) or d)QLQLVQSGAEVKKPGASVKLSCKASGYTFTSYTLHWVRQAPGQTLEWMGWINAGNGKTKYPPKFRGRVTITRDTSATTVDMHLSSLTSEDTAVYFCARGPESYYYDRSDWLNSHPDEYFQ YWGQGTLVIVSS (MAB699) or e)QVQLVESGADVKKPGASVTVSCKASGYTFRSFTMHWVRQVPGQRLEWMGWINAGNGKTKYSQKFQGRVIVTRDTSASTAYMELSSLTSEDTAVYYCARGPETYYYDSSNWLNSHPDEYLQ YWGQGTPVTVSS (MAB700) or f)QVQLVQSGADVKRPGASVTVSCKASGYTFRSFTMHWVRQVPGQRLEWMGWINAGNGKTKYSQKFQGRVIVTRDTSANTAYMELSSLTSEDTAVYYCARGPETYYYDSSNWLNSHPDEYFQ HWGQGTPVTVSS (MAB708) or g)QVQLQESGAEVKKPGASVQVSCKASGYTFTSYSVHWVRQAPGQRPEWMGWINAGNGKTKYPQKFKGRVTITRDTLARTVNIHLSSLTSEDTAVYFCARGPDSYYYDRNDWLNSHPDEYFQ HWGQGTVVIVSS (MAB710) or h)QVQLVESGAEVKKPGASVKITCEASGYTFNTYTIHWLRQAPGQRLEWMGWINAANGHTKYSRKLRSRVTIKRDTSARTSYMELSSLGSEDTAVYYCARGPETYYFDKTNWLNSHPDEYFQ HWGQGTLVTVSS (MAB711) or i)QVQLVQSGAAVNKPGASVKVSCKASGYSFTSYTLHWVRQAPGQRPEWIGWINAGNGKVKYPRKLQGRITITRDVSATTVHMELRSLTSEDTGLYYCARGPESYFFDTSNHLNSHPDEYFQ FWGQGTLVTVSS (MAB723).


7. The antibody or fragment of claim 6 whichin a) comprises a light chain having the sequenceDIQMTQSPGTLSLSPGERATLSCRASQSVSSNYLAWYQQKHGQAPRPLIYGASRRATDVPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPRT FGQGTKLEIK (MAB383) orin b) comprises a light chain having the sequenceDIVMTQSPDSLAVSLGERATINCKSSQTVLYTSNKKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYTSPYTFGQGTKLEIK (MAB486) orin c) comprises a light chain having the sequenceDIQMTQSPSTLSASVGDRVTITCRASQTINNYLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQEYNNDSPLT FGGGTKVEIK (MAB579) orin d) comprises a light chain having the sequenceDIQMTQSPSTLSASVGDRVTIACRASQSISSWLAWYQQKPGKAPKLLIYKASQLESGVPSRFSGSGSGTEFTLTINSLQPDDFATYYCQLYNVYSPLT FGGGTRVDIK (MAB699) orin e) comprises a light chain having the sequenceDIVLTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASTLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQEYNNNSPLT FGGGTKVEIK (MAB700) orin f) comprises a light chain having the sequenceDIQMTQSPSTLPASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQEYNNNSPLT FGGGTKVEIK (MAB708) orin g) comprises a light chain having the sequenceDIVMTQSPSTLSASVGDRVTISCRASQSIDSWLAWYQQKPGKAPKLLIYKASNLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQLYNVHLITF GGGTRVDIK (MAB710) orin h) comprises a light chain having the sequenceDIVMTQSPSTLSASVGDRVTITCRASQSISTWLAWYQQKPGKAPKLLIYKASNLESGVPARFSGSGSGTEFTLTISSLQPDDFATYYCQEYNNDSPLI LGGGTTVEIK (MAB711) orin i) comprises a light chain having the sequenceDIQMTQSPSTLSASVGDRVTITCRASQSISSYLAWYQQKPGKAPKLLIYKASNLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQEYNNNSPLT FGAGTKVEIK (MAB723).


8. The antibody or fragment of claim 6 which further comprises a heavychain comprising a) EVQLVESGGGLVKPGGSLRLSCAASGFTFSTYTMSWVRQAPGQGLEWVSSITRTSSNIYYADSVEGRFTISRDNAKNSLYLQMHSLRVEDTAVYYCARISGVVGPVPFDYWGQGTLITVSS (MAB8) or b)QVQLVQSGAEVRKPGSSVKVSCKVSGGIIRKYAINWVRQAPGQGLEWMGGIIAIFNTANYAQKFQGRVTITADESTSTVYMELSSLRSEDTALYYCARGMNYYSDYFDYWGQGSLVTVSP (MAB53).


9. The antibody or fragment of claim 8 whichin a) comprises a light chain comprising  the sequenceDIQMTQSPSSLSASVGDRVTITCRASQTISKYLNWYQQKPGRAPKLLIYSASSLQSGVPSRFTGSGSGTDFTLTITSLQPEDFATYYCQQSYRPSQIT FGPGTKVDIK (MAB8) orin b) comprises a light chain comprising  the sequenceEIVLTQSPGTLSLSPGERATLSCRASQSVRSNNLAWYQHKPGQAPRLLIFGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPAL TFGGGTKVEIK (MAB53).


10. The antibody or fragment of claim 1 wherein a heavy chain variableregion comprises a) CDR1 of the sequence AYTIH, and CDR2 of the sequenceWINAGNGHTKYSQRFKGR, and CDR3 of the sequence GPETYYYDKTNWLNSHPDEYFQH(MAB579); or b) CDR1 of the sequence SYTLH, and CDR2 of the sequenceWINAGNGKTKYPPKFRGR, and CDR3 of the sequence GPESYYYDRSDWLNSHPDEYFQY(MAB699); or c) CDR1 of the sequence SFTMH, and CDR2 of the sequenceWINAGNGKTKYSQKFQGR, and CDR3 of the sequence GPETYYYDSSNWLNSHPDEYLQY(MAB700); or d) CDR1 of the sequence SFTMH, and CDR2 of the sequenceWINAGNGKTKYSQKFQGR, and CDR3 of the sequence GPETYYYDSSNWLNSHPDEYFQH(MAB708); or e) CDR1 of the sequence SYSVH, and CDR2 of the sequenceWINAGNGKTKYPQKFKGR, and CDR3 of the sequence GPDSYYYDRNDWLNSHPDEYFQH(MAB710); or f) CDR1 of the sequence TYTIH, and CDR2 of the sequenceWINAANGHTKYSRKLRSR, and CDR3 of the sequence GPETYYFDKTNWLNSHPDEYFQH(MAB711); or g) CDR1 of the sequence SYTLH, and CDR2 of the sequenceWINAGNGKVKYPRKLQGR, and CDR3 of the sequence GPESYFFDTSNHLNSHPDEYFQF(MAB723).
 11. The antibody or fragment of claim 10 which in a) comprisesa light chain variable region which comprises CDR1 of the sequenceRASQTINNYLA and CDR2 of the sequence KASSLES and CDR3 of the sequenceQEYNNDSPLT (MAB579); or in b) comprises a light chain variable regionwhich comprises CDR1 of the sequence RASQSISSWLA and CDR2 of thesequence KASQLES and CDR3 of the sequence QLYNVYSPLT (MAB699); or in c)comprises a light chain variable region which comprises CDR1 of thesequence RASQSISSWLA and CDR2 of the sequence KASTLES and CDR3 of thesequence QEYNNNSPLT (MAB700); or in d) comprises a light chain variableregion which comprises CDR1 of the sequence RASQSISSWLA and CDR2 of thesequence KASSLES and CDR3 of the sequence QEYNNNSPLT (MAB708); or in e)comprises a light chain variable region which comprises CDR1 of thesequence RASQSIDSWLA and CDR2 of the sequence KASNLES and CDR3 of thesequence QLYNVHLI (MAB710); or in f) comprises a light chain variableregion which comprises CDR1 of the sequence RASQSISTWLA and CDR2 of thesequence KASNLES and CDR3 of the sequence QEYNNDSPLI (MAB711); or in g)comprises a light chain variable region which comprises CDR1 of thesequence RASQSISSYLA and CDR2 of the sequence KASNLES and CDR3 of thesequence QEYNNNSPLT (MAB723).
 12. The antibody or fragment of claim 10which is a bispecific antibody or fragment and further contains a heavychain variable region that comprises CDR1 of the sequence KYAIN, andCDR2 of the sequence GIIAIFNTANYAQKFQG, and CDR3 of the sequenceGMNYYSDYFDY (MAB53).
 13. The antibody or fragment of claim 12 whichfurther contains a light chain variable region that comprises CDR1 ofthe sequence RASQSVRSNNLA and CDR2 of the sequence GASSRAT and CDR3 ofthe sequence QQYGSSPALT (MAB53).
 14. (canceled)
 15. The antibody orfragment of claim 1 which is a bispecific antibody or fragment whichcomprises a heavy chain variable region that contains CDR1 of thesequence AYTIH, and CDR2 of the sequence WINAGNGHTKYSQRFKGR, and CDR3 ofthe sequence GPETYYYDKTNWLNSHPDEYFQH (MAB579), and a heavy chainvariable region that contains CDR1 of the sequence KYAIN, and CDR2 ofthe sequence GIIAIFNTANYAQKFQG, and CDR3 of the sequence GMNYYSDYFDY(MAB53), and a light chain variable region that contains CDR1 of thesequence RASQTINNYLA, and CDR2 of the sequence KASSLES, and CDR3 of thesequence QEYNNDSPLT (MAB579), and a light chain variable region thatcontains CDR1 of the sequence RASQSVRSNNLA, and CDR2 of the sequenceGASSRAT, and CDR3 of the sequence QQYGSSPALT (MAB53).
 16. (canceled) 17.The antibody or fragment of claim 1 which comprises the CDR3 of theheavy chain of MAB383, MAB486, MAB579, MAB699, MAB700, MAB708, MAB710,MAB711 or MAB723.
 18. A pharmaceutical composition comprising theantibody or fragment of claim
 1. 19. A method for the treatment orprophylaxis of influenza infection in a subject which method comprisesadministering to a subject an effective amount of the composition ofclaim
 18. 20. The method of claim 19 wherein the subject is infectedwith influenza.
 21. The method of claim 19 wherein the subject isprotected against influenza infection.
 22. A recombinant expressionsystem that comprises one or more nucleotide sequences encoding theheavy chain and/or light chain variable region of the antibody orfragment of claim 1 operably linked to control sequences for expression.23. Recombinant host cells modified to contain the expression system ofclaim
 22. 24. A method to produce a monoclonal antibody or fragmentimmunoreactive with influenza virus which method comprises culturing thecells of claim 23 under conditions wherein said nucleotide sequence isexpressed.